Belizatinib - Amgen

Alternative Names: TSR-011

Latest Information Update: 07 Feb 2018

Price : ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator Amgen
Developer TESARO
Class Antineoplastics; Benzamides; Benzimidazoles; Piperidines; Small molecules
Mechanism of Action Anaplastic lymphoma kinase inhibitors; Tropomyosin-related kinase antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Lymphoma; Non-small cell lung cancer; Solid tumours

Most Recent Events

31 Jul 2017 Chemical structure information added
14 Jul 2015 TSR 011 is still in phase I/II trials for Solid tumours, Non-small cell lung cancer and Lymphoma in USA and United Kingdom
14 Jul 2015 Phase-I/II clinical trials in Solid tumours, Non-small cell lung cancer and Lymphoma in Poland, Spain, Taiwan (PO)

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.